Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 24% below Graham Number ($26.57) — significant margin of safety
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 12.4% — below-average profitability
Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $890 million . Key value metrics: P/E ratio 11.1, P/B ratio 1.16, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Amphastar Pharmaceuticals, Inc. - Common Stock — Fundamental Analysis Summary
Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH) is trading 24% below its Graham Number of $26.57 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 11.1x.
On financial health, AMPH shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 12.4% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.77.
StockPik's composite Value Score for AMPH is 77/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
AMPH reports a solid gross margin of 48.1% (sector average: 39.4%) and a solid operating margin of 16.7%.
AMPH shows revenue declining at 2% year-over-year, with earnings declining at 39%.